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ABSTRACT
Gómez-Carrillo, Andrea. M.S.B.M.E, Department of Biomedical, Industrial and Human
Factors Engineering, Wright State University, 2021. Low Frequency Oscillations of
Hemodynamic Parameters as a Novel Diagnostic Measure for Traumatic Brain Injury

There is a need to improve methods of monitoring patients with traumatic brain injury
(TBI) in hospital settings. Current monitoring techniques and diagnosis methods are
expensive, invasive, do not provide continuous measures, expose the patient to radiation,
are ambiguous in the information they provide, and/or cannot be implemented at the
bedside. These techniques measure imperative markers of brain function including
intracranial pressure (ICP), cerebral blood flow (CBF), and oxygenation in the brain,
among others. Hospitals not only require a practical method for real-time monitoring of
patients at the bedside, but also meaningful metrics that characterize TBIs, since the variety
of methods results in complex and ambiguous criteria for defining TBIs. Trends in the
literature show a reliance on functional assessments such as the Glasgow Coma Scale
(GCS) to define TBIs, however studies have shown its complexity and context-dependence
in predicting outcome. Real-time cerebral assessment is currently focused on ICP
monitoring, but increased attention to hemodynamic measures to improve patient
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outcomes warrants new technologies and metrics. Therefore, in this thesis, a novel metric
of low-frequency oscillations (LFOs) from hemodynamic monitoring is proposed to
provide a more objective characterization of TBI. Literature suggests that these LFOs
originate from the regulation of regional changes in CBF and energetic metabolism and not
from systemic regulation of the cardiovascular system, making it a representative metric
of brain function. Overall, this thesis will contribute to the clinical understanding of TBI
through optical imaging-derived LFOs. To achieve this overall goal, the followings have
been investigated between non-TBI and TBI groups: 1) quantification of absolute
concentration changes of hemodynamic parameters, 2) assessment of the LFO spectrums
of the oxygenated hemoglobin signals to identify prevalent LFOs, and finally 3)
quantification of the average power in predefined LFO slow bands. The results indicate
that optical imaging can provide noninvasive neurovascular biomarkers for continuous
assessment of TBI patients.
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1. Introduction/Motivation
This section will provide the motivation behind this thesis. It includes a thorough
overview of TBI that highlights its prevalence and gaps in practical methods of its
diagnosis and management. It includes a summary of functional near infrared
spectroscopy (fNIRS) and its uses in the field, and finally it introduces low frequency
oscillations (LFOs) as a potential novel metric for TBI assessment. I conclude this section
with the implications of this project and its clinical significance.

1.1. Traumatic Brain Injuries
Traumatic brain injuries (TBIs) have been in conversation for a few centuries with
relevant literature dating back to 18915. A TBI is defined as a blow or jolt to the head,
which can disrupt the function of the brain6. Numerous events can lead to such damage,
including mechanical falls, traffic accidents; military combat injuries, and sports injuries
among others. Overall, there is a complicated variation in criteria and terminology when
assessing TBIs7, and the current modalities are not optimal for continuous real-time
monitoring or are invasive and place an already vulnerable brain at risk.
Various disciplines have examined this widespread health concern including nursing 6,
biomechanical/sports research 8–13, pediatrics 14–16, army studies 17, surgery 18,
rehabilitation 19,20, and neuropsychology/psychiatry 21–24, with an emergence in
engineering 25–31 among others. Articles, studies, and reviews assess TBIs from multiple
angles. From epidemiology 10,32–35, to etiology, to potential biomarkers for diagnosis 12,36–40,
various treatment approaches 41–47, and even studies that assess the correlation between
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player position in football and the risk of TBI13, the variety of perspectives surrounding
this topic corresponds to the complexity of addressing it clinically.
While in the 1990s the push was for more helmet use to prevent head injuries
after serious bicycle accidents48, and more recently the concern is to increase the
surveillance of TBI in youth sports 11, whatever the cause is, the prevalence of TBIs
remains concerning. Trauma is the third leading cause of death worldwide, just trailing
cerebrovascular disease and cancer49. TBIs contribute greatly to trauma-related deaths and
disabilities, accounting for almost one-third of injury-related deaths50. In the United
States, 5.3 million people are estimated to live with long-term disabilities due to TBIs, a
figure that underrepresents the injury’s incidence due to lack of reporting and diagnoses51.
In China, where brain-monitoring methods are not readily available5, there is also a high
prevalence of TBI2. A study on a brigade combat team accentuates the prevalence as
researchers found that roughly 23% of soldiers return with a TBI17. Not only is this issue
rampant in numerous contexts, but the ambiguity in assessing the human brain due to its
highly individualized nature also becomes problematic in diagnosing TBI. A study on the
accuracy of mild TBI diagnosis showed that 56% of patients who met the TBI criteria
from the Centers for Disease Control and Prevention (CDC) were not diagnosed by the
emergency department2. This means over half of the patients suffering from brain injury
walked out of hospitals unknowing of their condition. A phenomenon known as
secondary brain injury makes this a problematic statistic since impeded CBF due to the
initial impact continues to damage the brain post-trauma. Therefore, diagnosing the brain
becomes crucial, but current diagnostic methods are limited to self-reporting symptoms,
functional assessments such as the GCS, speech tests, language tests, cognition
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assessments, and neurophysiological tests. Occasionally, computed tomography (CT)
scans, magnetic resonance imaging (MRI), single-photon emission computerized
tomography (SPECT), or positron emission tomography (PET) are used to detect brain
bleeds and damaged tissue, but such techniques are not suited for long-term use and
might not even be ordered by physicians. Numerous studies acknowledge the
consequences of secondary brain injury, which increase the mortality from 10 to 56%53,
emphasizing that treatment should focus on preventing it. A recent review on TBI
advances outlines common treatments including anti-seizure prophylaxis, decompressive
craniectomy, hyperosmolar therapy, targeted temperature modulation to prevent
hyperthermia, and/or ICP monitoring43, 45. ICP monitoring is a recurring theme in the
literature and is arguably the most routine medical observation employed for TBI
patients. In an international survey of neurointensivists on the current practices of
neuromonitoring, they found that ICP monitors were the most available tool and the most
commonly used variable for the management of delayed cerebral ischemia (DCI), a
potential secondary brain injury54. Numerous articles over the past decades stress the need
for continuous monitoring to prevent secondary injury53,55–57, with managing ICP and
cerebral perfusion pressure (CPP) a main focus41–43,46,47,58. However, there is disagreement
on whether ICP or CPP-based management best benefits patients, warranting more
research on the management of TBI. Methods to manage pressure parameters such as
these are also inconsistent across hospitals, further complicating consensus on optimal
patient care. Feldman first validated elevating the head-of-bed (HOB) of patients as one
such method in 1992 in a study where he found a 30-degree elevation to be optimal in
reducing ICP while maintaining CPP and CBF59. This was later confirmed in a practice

3

audit by Schulz-Stübner et al.60 making this elevation standard positioning for ICP
management. However, recent studies in the pediatric population suggest that an optimal
elevation is not limited to 30-degrees and should be individualized to patients61. While
there are several other means of managing ICP including IV solutions, hyperventilation,
and surgical interventions62, other comorbidities of TBI deserve attention. One concern is
cerebral ischemia, which requires both CBF and oxygenation-based monitoring. A study
published in the Journal of Neurosurgery strengthens the need for additional metrics to
improve patient outcomes, as ICP/CPP management does not always prevent ischemia. In
the study, they found that adding brain tissue oxygen tension (PO2) monitoring to
traditional ICP monitoring reduced the mortality rate from 44 to 25%63. This is important
because it stresses the need to guide therapy with tissue oxygenation in addition to
pressure measures that are already in practice. Emerging protocols for TBI management,
especially in severe scenarios, combine both oxygenation and ICP measures to decide the
course of treatment. A recent article from the Seattle International Severe Traumatic
Brain Injury Consensus Conference is even attempting to develop an algorithm that
guides individualized treatment for patients with increased ICP but normal PO2, or
patients with normal ICP but decreased PO247. Recent attention to the combination of
oxygenation and pressure measures directs our focus to advance oxygenation and CBF
monitoring methods in hospital settings.
The assessment of CBF in TBI subjects can be traced back to 1978 in a study of
cerebral autoregulation (CA) of unconscious patients64. In the study, they utilized the
intra-arterial 133xenon washout method to measure rCBF and found regional
autoregulation loss in most studies64. This outdated method, however, requires local
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injection of xenon and was proven unreliable in later assesments65. The need for reliable
hemodynamic monitoring of TBI patients is where the previously mentioned modalities
of CT/PET/SPECT scans and MRIs can take snapshots of the brain and detect bleeds, but
do not provide the continuous feedback physicians need to identify deteriorating
conditions. Additionally, avoiding patient and physician exposure to radiation is a
widespread medical consensus, and the push away from CT is even strengthened by a
recent study showing that fast brain MRIs outperform them in specificity, sensitivity, and
negative predictive value of TBI diagnosis14. Regarding the disadvantages of PET and
SPECT, they both need a long measurement period to detect accumulated hemodynamic
changes and have low temporal and spatial resolution66. The historical alternative to
provide continuous monitoring has been functional MRI (fMRI), but it is limited to 1-2
hours of recording and is not ideal for the bedside. An MRI sequence of susceptibilityweighted imaging (SWI) has recently been proposed to detect cerebral micro bleeds
(CMBs) prevalent in TBIs that are undetectable in normal MRI and CT scans.
Researchers in the medical imaging field are investigating machine/deep-learning
methods using 3D-convolution neural networks to detect these tiny bleeds67, but it is still
a relatively new topic and beyond the scope of this thesis. Another emerging, radiationfree technology of magnetic particle imaging (MPI) for real-time perfusion monitoring
proves advantageous over these large machines in practicality, efficiency, and temporal
resolution and has been validated by MRI in mice studies68. The first in vivo study of TBI
patients also showed excellent contrast in showing changes in blood pool over time69,
however there is concern of the effects of time-varying magnetic fields on nerve
stimulation and even allergic reactions to the administered iron oxide nanoparticles have
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been reported70. MRI, MPI, SPECT, and PET modalities are also costly, therefore
limiting their use and posing a concern for underfunded healthcare settings where there is
not access to such technologies. Another method that has existed for over 50 years is
jugular venous oximetry, where fiber optic oximetry catheters are inserted into the
jugular bulb71, but it is invasive and rarely used72. Transcranial Ultrasound (US) Doppler
imaging has also been proposed as a more cost-effective and portable means of
quantifying blood flow velocity, which has been related to assessing cerebral
autoregulation and even corresponding ICP27, however its accuracy in this latter
relationship is in question73,74. The technique is also limited for longitudinal
monitoring because of relatively bulky US transducers, which make it hard to position the
US probe on the scalp. Thus, there is a need for a more practical method of continuously
monitoring of brain hemodynamics to manage TBI and is the focus of this thesis
research. For this overall goal, fNIRS technology is used for hemodynamic monitoring
and novel LFO analysis. FNIRS is noninvasive, safe, low-cost, portable, convenient for
bedside settings, does not require immobilization of the patient, has continuous
monitoring capabilities, and has high temporal and adequate spatial resolution75. Finally,
it has reliable data that has been proven by PET and fMRI76.

1.2. Functional Near Infrared Spectroscopy
Functional near-infrared spectroscopy (fNIRS) has been in conversation since the
late 1900s, notably beginning with a study on hemoglobin using a ‘Cary 14’
spectrophotometer to begin understanding hemoglobin’s oxygen affinity characteristics79.
Since then, it has expanded from a simple noninvasive method of measuring oxygen in
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tissues of cats80 to an enormous variety of applications. An optical imaging
modality, fNIRS, detects changes in the concentration of oxygenated (HbO) and
deoxygenated (Hb) hemoglobin as a means of assessing cerebral activity. Using a dualwavelength light emitter and photodetector, it can calculate blood volume and estimate
local oxygenation changes, with additional emerging capabilities in the field of TBI. In
the medical field, its applications have ranged from muscle studies including tissue
oxygenation during exercise, metabolic myopathy, and effects of lung diseases on
muscle83–88, to cancer-characterization studies including skin89, prostate90 and breast
cancer91,92, and even to type-I and type-II diabetes as a noninvasive glucose-monitoring
modality beginning in 199293–97. The variety of applications of fNIRS showcases its
potential as an established technology. For our purposes, we are interested in using it for
neuromonitoring. Its use in cerebral studies dates back to the late 1900s with
investigations on neurological diseases such as schizophrenia98–102 and Alzheimer’s
disease103,104. In the early 2000s studies incorporated migraine105, brain edema106, and optic
neuritis107. Task-related research also began to surface as studies evaluated brain function
during attention impairments23, cognitive rehabilitation20, and mental fatigue
assessments22. The complexity-task initially assessed by fNIRS in 201228 even evolved
into developing machine-learning biomarkers of TBI as spatio-temporal features proved
to be characteristic of brain injuries29. This successful use of fNIRS to characterize TBIs
affirms our selection of this technology for our project, although not in the same manner.
In fact, fNIRS has been finding its place particularly in infant brain studies partially due
to its ability to handle motion artifacts and higher light penetration depth in the infant
brain. More recent and innovative investigations involve interesting neural studies of
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OCD21, hemodynamic evaluation of trust in the only-child effect24, and even findings of
decreased cerebral oxygenation during mental tasks in subjects with type 2
diabetes108. The portability of fNIRS technology also allows it to be used in agricultural
technology, army and sport settings, and it has even been found that it could induce an
immune response to vaccines and be utilized in doctors’ offices109. Albeit compelling,
these recent applications of fNIRS are outside the domain of our project.
With the first fNIRS infant brain study dating back to 1998110 that assessed
regional hemodynamic responses to visual stimuli in awake infants, there have been over
thirty infant-related studies since111. Fox’s review on fNIRS-based infant studies provides
an adequate representation on the current signal processing methods used to derive
meaningful information from temporal light intensity changes that eventually give
hemodynamic information. They note that signal processing generally begins with lowpass filtering to correct linear trends, and then the Beer-Lambert law relates intensity
changes to concentration changes of HbO and Hb—with HbO generally accepted as the
preferred measure of cortical activation. This is applicable to our project as cortical
activation is of interest in patients with potential secondary brain injury. Regarding TBIs
specifically, studies show a decrease in HbO than normal due to cognitive impairment. In
a study comparing TBI subjects to healthy controls when receiving targeted and context
stimuli, significant decreases were found in the hemodynamic response between the two,
with reduced amplitude in the TBI group23. Another study found a higher increase in
HbO, Hb, and THC in TBI patients with head lowering when compared to healthy
patients145. This shows both the potential of fNIRS parameters and manipulating the head
of a patient’s bed to differentiate healthy and diseased states, which is the premise of this
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project. As previously mentioned, monitoring brain tissue oxygenation is crucial for TBI
management—making fNIRS ideal in clinical use. Its lack of use in hospitals112,113,
therefore, warrants questioning—especially since the reliability of fNIRS to provide
continuous hemodynamic data has been extensively validated over the years by
fMRI114 and has been well established for research purposes. TBI does bring some
complications to traditional fNIRS monitoring with interference from the scalp115 that is
exacerbated by stress responses from the TBI itself, and the presence of hematomas that
can misrepresent cerebral hemodynamics116. A review on the use of NIRS in TBI
concludes that it is mostly used in the identification of hematomas, but the reliance
largely remains on ICP monitoring for TBI management as the relationship of
hemodynamics and targeted therapy is not well-understood yet116. Some studies have
shown a potential relationship between ICP and NIRS parameters, but it is not sufficient
yet to contend that fNIRS should be utilized in clinical settings117,118.
We still believe there is great benefit in incorporating fNIRS to hospital bedside
monitoring and seek to reinforce the strengths of this technology by going beyond the
traditional time-series processing and reconstruction of functional images119 to new
metrics that can better characterize TBI. New signal processing methods in the frequency
domain (FD) are being experimented, with Welch’s method playing a key role in
estimating power spectrums. Recently, Welch’s method was used to
process fNIRS signals and successfully detect spontaneous frequency changes in
deceptive behavior120. We are proposing applying this type of frequency analysis to
further the knowledge of TBI characterization with new metrics.
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1.3. Low Frequency Oscillations
Frequency analysis of the brain is not a novel idea as electrical studies of the
cortex of rats date back to the mid 1900s121. Historically, it seems electroencephalography
(EEG) has been the dominant technique for assessing cerebral oscillations. The frequency
at which neurons fire in the brain has been widely shown to be representative of brain
function122 with five commonly categorized bands: delta (0.5–4 Hz), theta (4–8 Hz), alpha
(8–12 Hz), beta (12–30 Hz) and gamma (>30 Hz)123. Lower frequencies, however, are
only recently appearing in the literature as potential biomarkers of TBI. It is thought that
lower frequency oscillations (LFOs) may represent the regulation of changes in rCBF and
energetic metabolism rather than systemic regulation of the cardiovascular system4.
Additionally, numerous studies support that LFOs in the 0.07-0.1 Hz range can be linked
to CA124–126. These beliefs are exciting as they show the potential of directing research at
LFOs characterizing TBIs. While an EEG study on thalamocortical oscillations in sleep
and arousal from 1993 acknowledges the potential value of frequencies less than 1 Hz127,
and another study in Russia from 1988 recognized EEG frequencies of 0.2-2Hz in
patients with ablation of tumor surgery128, not many studies have investigated these faster
oscillations in the brain. LFO investigation through EEG-technology has recently
emerged in migraine studies where they define four characteristic bands of spontaneous
oscillation: slow-5 (0.01–0.027 Hz), slow-4 (0.027–0.073 Hz), slow-3 (0.073–0.198 Hz)
and slow-2 (0.198–0.25 Hz) and found an abnormal presence of these LFOs in the
thalamus associated with headache attacks129. Although the use of EEG to investigate
LFOs is relatively new, fMRI actually exists in LFO-related literature as early as 1995,
showing that the idea of fast hemodynamic oscillations might have been around longer
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than the lack of the presence of these metrics make it seem. In an early study, resting
fMRI showed that fluctuations lower than 0.1 Hz correlate with motor function and may
show the functional connectivity of the brain130. Other studies using the blood-oxygen
level dependent (BOLD) signal from fMRI also agree that ~0.08-0.1 Hz LFOs are an
intrinsic property of the brain that may modulate the well-known higher frequency
activity and play an important role in brain organization131–134. More recent uses of fMRI
include findings of LFO activity in the hippocampus representative of sensory
information integration135, and an interesting study was able to localize affected areas of
lower back pain in the brain from altered amplitudes of LFOs136. Furthermore, two
different studies on patients with retinal vein occlusion and non-neuropsychiatric
systemic lupus erythematous found LFO amplitude changes in multiple brain regions137,138.
This also showcases the strength of fMRI LFO-assessment in providing a spatial
discovery of neural mechanisms of diseases. Its application to TBI was introduced in an
fMRI study that found differences from healthy controls in the slow-4 and slow-5
frequency band amplitudes in occipital areas of the brain139. MRI, however, is limited to
only assessing Hb140 and with the limitations of fMRI previously
mentioned, fNIRS presents a practical alternative to LFO analysis. The first CBF LFOs
were found in Kato’s study from 2013 where 0.06-0.1 Hz oscillations in NIRS
parameters were representative of resting state brain function. In this study, they found
increased LFOs in preterm infants than term infants, suggesting an inverse correlation
between LFOs and brain function16. While this was the first use of NIRS parameters to
define LFOs, a study from 2008 used NIRS-based LFOs to calculate an estimate of
cerebral oxygen saturation (SvO2) that was validated by an intraparenchymal catheter141.
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The fact that this novel metric is already being validated as a means of estimating more
parameters adds to its potential as a future metric of TBI. A previously mentioned study
attempting to add machine-learning to identify biomarkers of TBI also looked into LFOs
from the HbO signal ranging from 0.01-0.1 Hz as characteristic of the disease during a
complexity task. They found this frequency feature was able discriminate between TBI
and healthy populations29, which is promising for this project’s analysis. An additional
biomarker arising from LFO analysis measured by fNIRS is the oxygen variability (OV)
index. Its ability to characterize TBI was validated in Chernomordik’s study comparing
cognitive load between brain-injured subjects and healthy controls140.
Another optical technology worth mentioning that has been applied to LFO
detection is with a Nikon epifluorescence microscope. In the study, they found dominant
frequencies of oscillations between 0.039 and 0.078 Hz in the cerebral cortex of a
tottering mouse to assess the neural events of dystonia142. This is interesting since these
are similar (the) frequencies of interest recently found in TBI LFO studies. As promising
as these studies are, they are scarce and TBI-related LFO analysis needs more research to
demonstrate itself in the field. With the need for a standardized method of continuous
real-time brain data, we present studying LFOs in TBI subjects undergoing a HOB
elevation change. HOB elevation manipulation has already been explained as a means of
managing TBI by lowering ICP while maintaining CPP.

1.4. Implications of this Project
We propose merging these numerous innovative insights and technologies surrounding
TBI to contribute meaningful knowledge to the field. By utilizing a fNIRS probe to
measure HbO and Hb as subjects undergo HOB elevation changes, we hope to provide an
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understanding of CA differences between TBI and healthy subjects. We plan to base our
protocol on Cheng’s assessment of healthy subjects undergoing a 70 degree elevation
change that was able to quantify CA by assessing phase shifts between the LFOs of mean
arterial pressure (MAP) and hemodynamic parameters30. While confident in their results,
they acknowledge the need to expand their study to subjects with cerebral impairment,
which is where this thesis project fills in by characterizing the cerebral response of a nonTBI and a TBI population undergoing HOB elevation changes using FD analysis of the
fNIRS signal. First, the frequencies of interest are identified, then LFO spectrums of each
study group are compared, and finally HOB of elevation changes on the LFO slow-bands
are quantified. In a broader impact, it is expected that this study demonstrates the
potential of fNIRS-LFO technology to assess brain injuries and diseases using a practical
HOB protocol, and to prompt future studies to eventually validate its use in hospital
settings.
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2. Materials and Methods
This section will outline the methods used in this project. We will include an overview of
participating subjects, the HOB manipulation protocol, theory behind optical
instrumentation and signal processing in the time and frequency domains.

2.1. Subjects
In total, this project utilized fifteen volunteers from Wright State University with mean
age of 23.8 years, range of 20-40 years. There were 7 males and 6 females of which one
female met the criteria of a TBI from a Glasgow coma score of 15 by their respective
athletic trainers. Due to the small sample size of TBI subjects, the sole TBI subject
underwent three measurements for a total of three recordings for the TBI population. For
the healthy population, each subject underwent one measurement. Two healthy subjects,
however, were excluded due to motion artifacts during their measurements resulting in
twelve recordings for the healthy population. The remaining participants had a mean age
of 25.5 years and a range of 20-40 years. Both populations, TBI and healthy, underwent
the same ten-minute measurement protocol after a five-minute baseline stabilization
period where no measurements took place. The International Review Board of Wright
State University approved this protocol and participants consented to the measurements.

2.2. fNIRS System
This project used the fNIRS system (OxiplexTS™ instrument from ISS) to
measure HbO and Hb concentrations in tissue. The sensor of this fNIRS system consists
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of eight laser diode sources and a photomultiplier tube (PMT) as a detector. This 8channel array sits in a black polyutherane rubber sensor with a side entry for the fibers,
adding flexibility to the design143. Source-detector pairs are 1.5, 2.0, 2.5, 3.0 cm apart,
and an average optical power of less than 1 mW makes the device comply with ANSI
safety standards. It works in the FD by modulating NIR light at 110 MHz into tissue at
two different wavelengths (830 nm and 690 nm) and exporting the collected signal as an
ASCII file that is processed in MATLAB 2018b. Light information traverses through a
microprocessor and sends the signal to the computer as intensities through a USB
cable. With the assumption that hemoglobin acts as the main absorber, the instrument
can uniquely determine absorption and scattering coefficients, and thus
calculate HbO and Hb concentrations143. Figure 1 below shows the main components of
the system.

FIGURE 1: (Top) The Oxiplex TS system with fibers providing connection to the sensor and a USB cable
communicating with the computer143. (Bottom) A schematic detailing the dimensions of the optical probe
that holds the fibers143 with the actual probe pictured on the right.
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2.3. Head-of-Bed Protocol
Each subject underwent the same 15-minute HOB protocol. Subjects received
explanation of study procedures and provided consent prior to beginning the
measurements. The sensor was placed on the left side of the dorsolateral prefrontal cortex
(DPFC) as shown in Figure 2 below. To properly place the sensor, an EEG cap was used
with markings that referenced the international EEG 10-20 system as shown in Figure 2
below.

FIGURE 2: (Left) Example of EEG cap used to guide marking of Fp1 position. (Right) Diagram
describing the location of the nasion and inion used to guide the EEG cap placement on the vertex of each
subject.

The cap placement was then guided the source and detector locations. To properly place
the cap, the distance from each subject’s nasion to inion was measured with tape.
The Cz position on the cap was then placed at the halfway mark of this distance and the
cap was adjusted to symmetrically fit on the subject’s head. A small marking was placed
slightly above the subject’s left Fp1 position to guide the sensor placement once the cap
was removed. The sensor’s source optode was then placed on the Fp1 position (slightly
below the marking) so that the marking would not interfere with the signal and the entire
sensor was secured using a black elastic band around the subject’s head. Final placement
is visible in Figure 3 below.
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FIGURE 3: (Left) Location of marking on the Fp1 position from the International 10-20 system and the
placement of detectors and sources. (Right) Location of sensor on subject’s left dorsolateral prefrontal
cortex.

The elevation changes in this project were facilitated using the HILL-ROM 1105
Advance Hospital Bed from Piedmont Medical Incorporated as shown in Figure 4. The
electric bed features side rail controls that adjusted the angle of elevation of the
headboard. The footboard could also be manipulated but was not used in this project.

FIGURE 4: HILL-ROM 1105 Advance Hospital Bed used for elevation changes during measurements.

Once the sensor was properly placed, subjects were asked to sit in the thick foam mattress
of the bed at the initial 30-degree elevated position and relax for five minutes. After this
five-minute relaxation period that established baseline conditions, the fNIRS
system started a five-minute head-up-tilt (HUT) recording. The bed was then lowered to a
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zero-degree angle at a rate of 2.5 degrees per second and recording continued for five
more minutes. Figure 5 below outlines the three phases of this protocol.

FIGURE 5: The three phases of the HOB protocol: Phase 1 was baseline establishment as the subjects
rested in an elevated position, phase 2 measurements began at the elevated position for 5 minutes, phase 3
measurements continued at the resting supine position for five minutes.

2.4. FNIRS Theory
One can determine concentration changes of oxygenated and deoxygenated hemoglobin
from light received by a detector because human tissue absorption is mainly due to
hemoglobin in the blood at the near infrared wavelengths [650 nm-900 nm]. Figure 6
below shows the most probable paths photons take for given source and detector
configurations.

FIGURE 6: (Left) The diagram shows path of light from 4 emitter fibers to the detector on the Imagent
sensor used in this project143. (Right) The banana shape of how light diffuses through the scalp, skull, and
cerebral cortex before returning to the detector.
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Photons emitted from the diodes propagate through the scalp, skull, and brain tissue. This
photon propagation is mainly governed by photon diffusion, dominated by the light
scattering, which allows photons to propagate deep into the tissue. Most of the photon
paths from source to detector follow banana-shaped paths, as seen in Figure 6. Some of
the photons are absorbed by the tissue chromophores. Chromophores are physiological
substances that absorb light. In brain tissue, the main chromophores are HbO, Hb, and
water in the NIR wavelength region. The absorption spectra of major absorbers can be
seen in Figure 7 below.

FIGURE 7: Absorption spectrum of HbO, Hb, and water with the optical window highlighted in blue 143.

The two wavelengths used in this optical technique are chosen because of
the differences between the absorption properties (or extinction
coefficient (ɛ)) of HbO and Hb and the minimal absorption of water. This contrast allows
for differentiation between the two chromophores more accurately. The first wavelength
used, 690 nm, is in a region where absorption for Hb is significantly higher than HbO,
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and conversely the second wavelength used, 830 nm is in a region where absorption
for HbO is higher. The intensity of light received at the detectors helps define absorbance
(A) through Equation 1 below, where T is the ratio of light seen by the detector (I) to the
initial incident light (Io).
𝐴=−log(𝑇)

[1]

Absorbance is a function of each chromophore’s extinction coefficient (ɛ) as a product of
its concentration and can be related through the absorbance coefficient, µa, as is shown in
Equation 2 below.
𝜇𝑎=𝜀𝐻𝑏𝑂[𝐻𝑏𝑂]+𝜀𝐻𝑏[𝐻𝑏]+𝜀𝐻2𝑂[𝐻2𝑂]

[2]

Extinction coefficients are established values unique to each chromophore and
wavelength in units of µM M-1 cm-1, and they can be obtained from a look-up
table. The OxiplexTS system assumes water concentration is set
at 70% as the background absorption, which leaves the concentrations of HbO and
Hb as the only two unknown values. µa becomes a measurable parameter through Beer
Lambert’s Law shown in Equation 3 below, and therefore detecting intensity changes at
two different wavelengths allows for both concentrations to be calculated.

[3]
However, since photons received by the detector represent both absorbed and scattered
light, a modified Beer-Lambert law (MBLL) must be used to account for the dispersion.
This modified equation accounts for scattering with a scattering coefficient µs’.
The OxiplexTS can calculate both the scattering and absorption coefficients by
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using FD spectroscopy where the diodes are modulated at 110 MHz. This means incident
light becomes a function of time with phase (∅), DC and AC components
𝐼𝑜=𝐼𝐷𝐶+𝐼𝐴𝐶sin(2𝜋𝑓𝑡−∅). The relationship between these parameters as measurements
take place can be seen in Figure 8 below from the OxiplexTS Manual143.

FIGURE 8: Light is modulated at 110 MHz in the FD technique used by the Imagent system to allow for
determining absorption and scattering parameters. The phase shift from the delay in light emitted to light
received provides the information necessary for this determination.

The amount by which these components and phase change as a function of sourcedetector separation allows for µa and µs’ to be determined. The experimental data in the
output includes values of the DC, AC, and phase components of the signal. It is exported
as an ASCII file and imported to MATLAB 2018b where a custom code is used to
process the data.

2.4. Signal Processing
The custom-written MATLAB 2018b program processes the signal obtained through the
following sequence:
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The ASCII file from the OxiplexTS is imported to MATLAB 2018b as a table and
transformed into a matrix. The time-series component of the output is formatted into 8
columns of direct current (DC) intensities and 8 columns of alternating current (AC)
intensities. There are 8 columns of each because the combination of two wavelengths and
four source-detector (Ri) separations results in eight paths of light passing through the
cortex. We isolated the DC columns and adjusted these intensity values to each subject’s
absorption & scattering properties (Equation 4). The DC correlation factor (DCCF)
adjusted the intensities to how well the system was estimating these properties and can be
seen in Equation 4 above. We then calculated changes in optical density (OD) for each
wavelength and Ri combination from intensity changes between initial light and
outputted light using Equation 5 as shown above. These OD changes can be related to
the concentrations of hemoglobins, the differential path-length factor (DPF) specific to
each wavelength, and each Ri as is also shown in Equation 5. The MBLL (Equation 6)
was then used to determine concentration changes for each chromophore using matrix
algebra. The result was four arrays of concentration changes for HbO and Hb from which
THC was calculated using Equation 7. The Z-score , shown in Equation 8, was then
used to center and normalize these concentration parameters as was done in a previous
study144. The average of the four channels of each chromophore were used to obtain a
single array for each normalized concentration parameter that increased signal-to-noise
ratio (SNR).
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For extracting LFO intensities from normalized concentration changes, Welch’s method
was used to obtain its power spectral densities (PSDs), as was done in previous studies30,
31, 124

. Before beginning segmentation, the normalized arrays were filtered into specific

time segments of the HUT and Rest positions to avoid capturing the transition period and
focus the analysis on the two elevations. Chri in the diagram above represents the three
time-series arrays analyzed by the following methods. Welch’s method divided the timeseries array into eight segments with 50% overlap. The frequency response of each of
these segments were obtained by Fast-Fourier Transform (FFT) using the FFT command
in Matlab and then they were averaged to obtain smoother spectrum (Equation 9). This
spectrum had a frequency resolution of ~0.027 Hz, obtained by dividing the sampling
frequency (fs), by the length of each segment. The LFO intensity was then obtained using
Equation 10 where Fx*(f) was the complex conjugate of Fx(f) and f was in the low
frequency range of 0.05 to 0.15 Hz. The result was a PSD in units of (M2/Hz) for each
trial. The final analysis was then performed on JMP Pro 15 and Microsoft Excel.
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3. Results and Discussion
3.1. Hemodynamic Concentration Changes

While this project focuses on the frequency analysis of the fNIRS time-response signal,
we first assessed the time-response of the concentration changes affected by lowering the
HOB from the HUT position to the resting position. To do this, we calculated the
difference in concentrations at each elevation processed through the written program in
MATLAB 2018b explained previously. The Equations [11-13] below show the resulting
parameters used for the hemodynamic concentration change analysis for each
chromophore.
ΔHBO(t)=[ΔHBOHUT](t)-[ΔHBOSup](t)

[11]

ΔHB(t)=[ΔHBHUT](t)-[ΔHBSup](t)

[12]

ΔTHC(t)=[ΔTHCHUT](t)-[ΔTHCSup](t)

[13]

3.2.1 Oxygenated Hemoglobin Changes from HOB Lowering
The individual and group mean concentration changes of HbO are shown in Figure 9
below. The change in an individual chromophore concentration is depicted as an absolute
value and trials 3, 7, and TBI1 in Figure 9a represent a decrease in HbO concentration
when the HOB was lowered rather than an increase. The change in mean chromophore
concentration takes these decreases into account.
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(a)

(b)

FIGURE 9: (a) Individual and (b) group mean changes in oxygenated hemoglobin as they went from HUT
to resting positions. The non-TBI trials are depicted in green and the TBI trials are depicted in red.

Overall, both groups had HbO increase as the bed lowered from HUT to the resting
position despite both experiencing individual trials with decreases in HbO. The non-TBI
trials had greater concentration changes with the HOB manipulation with a difference of
0.15 M. These results are consistent with previous studies where an elevated position
shows lower HbO concentrations than a resting position.

3.2.2 Deoxygenated Hemoglobin Changes from HOB Lowering
Figure 10 below shows the individual and group mean concentration changes of Hb. In
Figure 10a, trials 5, 6, 10, 11, 12, TBI 1 and TBI 3 represent a decrease in concentration
when the HOB was lowered.
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(a)

(b)

FIGURE 10: (a) Individual and (b) group mean changes in deoxygenated hemoglobin as they went from
HUT to resting positions. The non-TBI trials are depicted in green and the TBI trials are depicted in red.

Overall, Hb increased in the TBI trials when going from HUT to resting. Non-TBI, on the
other hand, saw an overall—albeit small, decrease in Hb concentration when lowered to
the resting position. With the difference of 0.58 M, there are distinct effects between
groups regarding deoxygenated blood. The non-TBI trials are consistent with previous
studies where Hb concentration decreases at the resting position. The mean effect of Hb
concentration increasing in TBI, and even more significantly than its HbO increase,
suggests a potential issue with regulating blood flow in injured brains.

3.2.3 Total Hemoglobin Changes from HOB Lowering
Figure 11 below shows the individual and group mean concentration changes of the total
hemoglobin response. As with changes in the HbO signal, trials 3, 7, and TBI1 in Figure
11a represent a decrease in concentration when the HOB was lowered.
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(a)

(b)

FIGURE 11: (a) Individual and (b) group mean changes in total hemoglobin as they went from HUT to
resting positions. The non-TBI trials are depicted in green and the TBI trials are depicted in red.

Overall, both groups had a total increase in hemoglobin concentration as the bed lowered
from HUT to the resting position. A large increase of HbO in the non-TBI trials and both
HbO and Hb increasing with HOB lowering contributed to more blood present at the
resting position. Comparing between non-TBI and TBI, the magnitude of changes of
HbO and THC was more pronounced in TBI subjects with Hb substantially changing in
the TBI trials. This latter effect of Hb is inconsistent with a previous study where HbO
was the main influencer on THC. That specific study, however, assessed healthy
populations whereas this discrepancy occurs in a brain-diseased population. This further
strengthens the idea that injured brains regulate blood flow differently than healthy ones.
Figure 12 below summarizes the hemodynamic concentration changes discussed in this
section.
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FIGURE 12: Summary of group mean changes in oxygenated (red), deoxygenated (blue), and total
hemoglobin (black) as they went from HUT to resting positions.

3.3. Changes in Low Frequency Oscillations
Initially, viewing the data from a frequency analysis yielded ambiguous results. To assess
the changes in frequency response of a subject from HUT to the resting position, we
generated an average low frequency spectrum during the two respective elevations were
generated.
We excluded the data during the time the bed was actively being lowered from 30° to 0°
to exclude transition effects and isolate the positions of interest. A representative timeseries data is shown in Figure 13, where the HUT and Rest time-segments are labelled,
which indicates the time periods isolated to represent HUT and resting positions. Future
studies could look at these transition periods to investigate whether frequency or time
domain information during the transition could characterize trauma in the brain, however
this was beyond the scope of this project.
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FIGURE 13: Example time series of a non-TBI trial showcasing the time-series filtering of the signal to
separate HUT and Rest to be representative of the elevations only and exclude the transition effects.

To characterize TBI and the impact of changing a subject’s elevation we divided our
observations into two comparisons: 1) between study groups at each elevation, and 2)
between elevations within each study group.

3.3.1 HUT comparison between study groups at each elevation
These frequency responses are shown in Figure 14 below. The responses include a nonTBI plot during HUT (Fig.14a), a non-TBI plot during the resting position (Fig.14b), a
TBI plot during HUT (Fig.14c), and a TBI plot during the resting position (Fig.14d).
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(a)

(b)

(c)

(d)

FIGURE 14: Frequency spectrums of the average of all HbO trials within each group: (a) the non-TBI
spectrum during HUT, (b) the non-TBI spectrum at the resting position, (c) the TBI spectrum during HUT,
and (d) the TBI spectrum at the resting position.

Comparing between Figure 14a and Figure 14c, the frequency response between non-TBI
and TBI at the elevated (HUT) position is generally similar in shape. Both groups show
significant activity within the [0.1-0.15] Hz range and a smaller, yet notable response
beginning at ~0.2 Hz. The significant activity around 0.1 Hz is consistent with previous
studies of spontaneous LFOs where they were observed in MAP and CBFV signals30.
Interestingly, their PSD is similar between the two groups at this HUT position, with max
intensities of ~0.08 M2/Hz. This suggests and strengthens the findings of previous studies
of an intrinsic neuronal mechanism occurring at this 0.1 Hz oscillation and could be a
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frequency of choice when comparing between healthy and diseased states. With this thesis
showing a similar PSD distribution in this elevated HUT position at 0.1 Hz, this could
allude to the cerebral response favoring and regulating at a normal level in the HUT
position, regardless of it is injured or healthy. Figure 14c, however, provides insight on a
frequency that could differentiate TBI in the HUT position. There is a significant increased
response at ~0.027 Hz in the TBI group at HUT that is not observed in the non-TBI group
at HUT. This is consistent with a study comparing children with autism spectrum disorder
(ASD) and typically developing (TD) children where they observed stronger fluctuation
magnitude in the 0.0200-0.0333 Hz band in ASD trials that did not exist in their TD trials.
In that study, subjects were also at an elevated position as they were asked to sit upright in
a chair with their eyes closed during measurements. In our project, this stronger fluctuation
is not present in the TBI trials at the resting position suggesting that the ~0.027 Hz
frequency could be associated with a mechanism in the injured brain trying to autoregulate
at an elevated position. Since this project had limited TBI subjects to sample, this presents
an opportunity for future studies to focus on this frequency band in injured individuals
specifically at an elevated position.
Regarding the spectrum distribution, the TBI trials show a narrower response than the nonTBI trials, but this is most likely due to the higher variability present in the non-TBI group
from including more subjects. This is more easily seen when looking at each individual
trial in Figures 15a and 15c where the individual LFO spectrums from each trial of the two
study groups at both elevations are shown.
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(a)

(b)

(c)

(d)

FIGURE 15: Frequency spectrums of individual HbO trials within each group: (a) the non-TBI spectrum
during HUT, (b) the non-TBI spectrum at the resting position, (c) the TBI spectrum during HUT, and (d)
the TBI spectrum at the resting position.

Within the 0.1-0.15 Hz band where stronger fluctuations existed in the averaged response,
one can see stronger fluctuations in narrower frequencies specific to each individual
subject. One non-TBI subject, for example had a notable response closer to ~0.11 Hz while
another saw this stronger magnitude closer to ~0.14 Hz. Regarding the increased average
response beginning around ~0.2 Hz, it is clear that this was largely influenced by one
specific non-TBI subject seeing a notable increase in magnitude around ~0.225 Hz where
another non-TBI subject saw this closer to ~0.25 Hz. This latter healthy response is more
consistent with the TBI subject who also saw stronger magnitude closer to ~0.25 Hz
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suggesting that this oscillation range beginning at ~0.2 Hz is intrinsic to CA mechanisms
and was not affected in this specific TBI subject.
These results suggest that the LFO metric could also be an individualized tool to
compare a subject’s normal functioning frequency response to their diseased response
rather than a group average comparison between injured and non-TBI populations. While
this requires a closer look at intrasubject variability, Figure 15c indicates similar frequency
responses between the TBI subject’s three trials during HUT. This subject consistently had
stronger magnitude fluctuations around ~0.12 Hz. These repeatable LFO responses present
a high potential for individualized diagnostic measures for the brain using a practical and
low-cost tool in fNIRS. However, studies with higher sample sizes should investigate this
further as repeated measurements were only taken for the single TBI subject whereas the
non-TBI subjects received only one measurement each.
While there is high potential with studying intersubject variability and individual
diagnosis, the averaged response of larger populations such as TBI and non-TBI should
not be ignored as certain frequency bands of interest can be identified. The consistently
increased spontaneous activity around frequency bands of 0.1-0.15 Hz and ~0.2 Hz
between all averaged TBI and non-TBI trials suggests these frequencies may be of high
interest for CA assessment at elevated positions.

3.3.2 Rest comparison between study groups at each elevation
Comparing between Figure 14b and Figure 14d, the non-TBI trials exhibit significant
activity in the 0.1-0.17 Hz range in the resting position while the TBI trials also see activity,
but from the 0.1-0.14 Hz range. There is also a rise in fluctuation beginning at the ~0.2 Hz
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in the non-TBI group while this increase in activity begins at ~0.225 Hz for the TBI trials.
This is inconsistent with the previous study mentioned where the only significant frequency
response was from the HUT position and the flat resting (Rest) position did not show peaks
near ~0.1 Hz. A difference in protocol could explain this discrepancy. In that study,
subjects were first measured in the flat resting position and then transitioned to the HUT
position. In this project, on the other hand, subjects were initially measured in the HUT
position and then lowered to the flat resting position. The frequency activity present in this
project could therefore still be indicative of a lingering cerebral mechanism from an
elevated posture and future studies should consider measuring the flat resting position prior
to the HUT position. The presence of ~0.1 Hz frequency activity in both the non-TBI and
TBI trials at this resting position shows that trauma to the brain in this subject did not affect
the underlying mechanism that this 0.1 Hz oscillation represents. In fact, the PSD is
stronger in magnitude in the TBI trials compared to the non-TBI trials, however more TBI
subjects are necessary to ensure it is representative of the TBI population and not unique
to this subject.
Similarly to the HUT discussion, Figure 14b and Figure 14d related to the resting position
also shows the limitations of drawing conclusions based on group averages characteristic
of the TBI population. This is evident from the frequency response of individual non-TBI
subjects in Figure 15b. A few of these non-TBI trials exhibit stronger magnitude near the
same ~0.11 Hz frequency as the TBI trials. Others exhibit a similar response again between
non-TBI and TBI near the ~0.25 Hz frequency and suggest LFO analysis to characterize
TBI should be considered on a case-by-case basis.
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3.3.3 Non-TBI comparison between elevations within each
study group
Comparing between Figure 14a and 14b, the non-TBI subjects show a wider LFO range
at rest than at HUT. The lower variability in the HUT position of the same subjects could
suggest two things: 1) it conveys higher precision power in measuring subjects at an
elevated position, and/or 2) there is recruitment of more underlying mechanisms for CA
that are represented by more frequencies at the flat resting position than at an elevated
position. The first theory is supported by the previously mentioned study by Cheng et al.30.
In the frequency response from the flat resting position, their healthy subjects had low
success rates for identifying LFOs with large frequency ranges (0.078-0.086 Hz) and
standard deviations. Conversely in the HUT position, their subjects exhibited 100% success
rates for identifying LFOs and a focused ~0.076 Hz response with smaller standard
deviations. Regarding PSD magnitude, the HUT position shows a higher overall magnitude
for the non-TBI trials compared to the resting position for the same trials. A predominant
difference between HUT and resting position is observed at around 0.115 Hz. This
frequency is notable in the HUT position but significantly lowers in the resting position.
Conversely, a peak in the frequency ~0.14 Hz in the resting position does not exist in the
HUT position.
From Figures 15a and 15b, it is evident that this differentiation between HUT response
and flat resting response results from individual subjects rather than a group average. The
peak at ~0.14 Hz results from only two subjects exhibiting a significant response in this
region, while most subjects did not contribute to the peak. Additionally, the widened
response that includes more frequencies in the resting position than in the HUT position is
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the result of two different individuals. In Figure 15b, one can see the subject represented
by the yellow spectrum is responsible for the widening of the averaged response as it
showed a peak near ~0.1 Hz that was not present in the HUT position. The subject
represented by the red spectrum is responsible for the widening of the averaged response
on the other side of the range as it shows a peak near ~0.17 Hz that was not present in the
HUT position. Therefore, the widening was not the result of a single subject going from
HUT to rest, but rather a larger variation in a few subjects. These individual responses
support the second theory that there could be underlying mechanisms for CA expressed in
these two individuals that are not recruited at an elevated position. However, since they are
only present in two trials it would require further investigation and favors the idea that LFO
responses are unique to each subject’s normal functioning. On another hand, a higher
overall power in the HUT responses shows the strength of using this elevated head position
as a reliable protocol for assessing LFO responses.

3.3.4 TBI comparison between elevations within each study
group
Comparing between Figure 14c and Figure 14d, the frequency response does not seem to
change much from HUT to rest in the TBI trials, especially around the 0.1-0.14 Hz range.
The strongest PSD magnitude in both positions around ~0.12 Hz is also consistent in power
between the two positions. When looking at the activity beginning near ~0.2 Hz,
fluctuations are present in both positions, as was seen in the non-TBI trials. However, the
overall power is higher in the resting position compared to the HUT position here whereas
in the non-TBI trials the power in this frequency region remained fairly similar and even
showed an overall decrease at the resting position. The most prominent difference,
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however, between the HUT and resting position in these TBI trials is the peak seen in the
HUT position at ~0.027 Hz that is negligible in the resting position. This peak is also not
present in either position in the non-TBI trials. As was previously mentioned, this
observation correlates with responses seen in the study on ASD children measured at an
elevated position. The ~0.027 Hz frequency, therefore becomes an identifiable feature of
diseased brain states and should be followed up in subsequent studies.
Regarding the individual TBI trials in Figures 15c and 15d, the LFO responses remain
consistent when going from HUT to rest. The main difference is a higher power in one of
the trials in the ~0.12 Hz peak that was countered by a lower power in the other two trials
which resulted in a consistent averaged response. The lack of change in the LFOs when
going from HUT to resting in these TBI trials differs from the individual non-TBI
changes when going from HUT to rest. In those non-TBI trials, subjects either showed
increased or decreased magnitudes in their PSD at these observed frequencies. This
suggests that the injured brain did not respond adequately to a change in elevation
whereas non-injured brains usually adjust their underlying mechanisms when undergoing
elevation changes. This is another hypothesis that should be considered in future studies
with larger sample sizes and shows the strength of using HOB manipulation to
characterize TBI. The repeatability of responses in the three trials from this TBI subject,
however, show the strength of fNIRS to identify meaningful LFOs in studying trauma in
the brain. Therefore, in future studies with larger sample sizes, fNIRS and LFO analysis
remains a suitable metric for characterizing TBI.
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3.3.5 Defining frequencies of interest through prevalence
analysis
To further identify frequencies of interest to guide future LFO analysis in the TBI
population, the prevalence of increased activity of certain frequencies was analyzed. To do
this, peaks at specific frequencies from the spectrum of each subject were identified using
the program built in MATLAB 2018b and a count was kept of each frequency of interest
as well as its PSD magnitude value. A frequency was considered a peak if its PSD
magnitude was greater than the value of its neighbouring observations. An example of an
individual subject’s peak data collection is included in Figure 25 in the Appendix. The
peak frequencies of each trial were then compiled into one table and imported into JMP
Pro 15 for the prevalence analysis. The distribution of peak frequencies for each population
at each elevation was then plotted on JMP and is visible in Figure 16 below. We limited
our analysis of frequencies up to 0.1 Hz to compare to previous studies’ focus on these
LFOs. However, previous studies did not look at prevalence as a metric. It serves more of
an observational premise to guide future studies to LFOs of interest.
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FIGURE 16: JMP distribution of peak frequencies for each population at each elevation.

Peaks near ~0.013 Hz were prominent in non-TBI trials with a similar slightly higher
prevalence in the resting position. In TBI trials, this frequency was significantly more
pronounced in the resting position. The 0.04 Hz LFO also was present in numerous
spectrums, consistently in the non-TBI group and more prevalent at the resting position in
the TBI group. Peaks near ~0.053 Hz also warrant attention as they are prominent in the
HUT position in both non-TBI and TBI trials and drop in prevalence when going to the
resting position. The ~0.067 Hz peak is also notable in non-TBI and TBI trials, remaining
fairly consistent among elevations. The ~0.08 Hz peak slightly increased in prevalence
when comparing HUT to resting in both groups. This specific LFO is also mentioned in
previous studies as a potential intrinsic property of the brain that plays an important role in
brain organization131–134. Its smaller prevalence in the TBI trials at the HUT position
conveys that ~0.08 Hz could be characteristic of an underlying mechanism that becomes
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affected with trauma to the brain. The ~0.093 Hz peak emerged as the most prevalent LFO
and is fairly consistent in the HUT and resting positions for the non-TBI trials, while it
slightly lowers in the resting position. Like the ~0.08 Hz peak, this ~0.093 Hz peak could
be a defining frequency that should be considered in future TBI studies. The ~0.1 Hz was
also prevalent in both groups and remained fairly consistent in prevalence as a peak
between HUT and the resting positions. These last three frequencies identified as potential
LFOs of interest belong to a range of frequencies that several studies say may be linked to
CA124–126 Additionally, they belong to the slow-3 band described in the following analysis.

3.3.6 Slow Bands Analysis
As was previously mentioned, the research community has begun to define frequency
ranges representative of brain functions in these lower frequency values. Termed “slowbands”, these five ranges are garnering attention in characterizing brain disease in a variety
of technologies including EEG, fMRI, and fNIRS. The slow-5 band includes 0.01–0.027
Hz, the slow-4 band includes 0.027–0.073 Hz, the slow-3 band includes 0.073–0.198 Hz,
the slow-2 band includes 0.198–0.25 Hz, and the slow-1 band includes 0.5-0.75 Hz. Figure
17 below shows the individual and averaged spectrums of all trials for the non-TBI
population and Figure 18 shows them for the TBI population during the entire
measurement period. This means frequencies present during the transition period are
included in these spectrums.

41

42

FIGURE 17: The individual trials and averaged spectrums of each slow band for the non-TBI population.
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FIGURE 18: The individual trials and averaged spectrums of each slow band for the TBI population.
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Two approaches used to provide quantitative metrics from these bands included: 1)
averaging the power spectrum of each band and 2) isolating the maximum PSD magnitude
within each band. The latter was chosen as a method of interest from the presence of
discrete peaks in the spectrums that are especially observable in the slow-2 and slow-3
bands. Maximum values within each band, therefore, characterize the more prevalent
frequencies and could provide valuable information that an averaged value might conceal.
This is most important when assessing the slow-3 band where most subjects saw
pronounced activity near the 0.1 Hz frequency rather than representing the entire 0.0780.198 Hz range. Therefore, the overall average value obtained from the slow-3 band for
each population largely differs from the average maximum power in this band.

3.3.7 Slow Band Average Power Analysis
For the first analysis, the average PSD magnitude of each slow band was obtained from
each trial using the program created in MATLAB 2018b. We separated each trial’s average
PSD within each slow band at both HOB positions (HUT and Rest) using the time-series
filtering previously described. Figure 26 in the Appendix shows an example of the
individual spectrums of one subject at the two HOB positions. The average PSDs in units
of uM2/Hz for each trial were recorded in Table 3 found in the Appendix. Percent change
was then used to assess the effects of HOB manipulation and observe if differences existed
between the non-TBI and TBI trials at the two elevations. Percent change is defined in
Equation 14 below and this data is included in Table 4 in the Appendix.
% Change = 100 x (PSDHUT – PSDREST )/ PSDREST
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[14]

From the percent change data, we assessed changes by determining the prevalence of
average power increases (APIs) and decreases (APDs) when comparing the HUT position
to the Rest position. An API was defined as a positive percent change from a higher power
present at HUT, and an APD was defined a negative percent change and a lower power
present at HUT. In the non-TBI population, APIs were more prevalent at the HUT position
for the slow-3 and slow-5 bands, APDs were more prevalent for the slow-1 band, and the
prevalence was equal of APIs and APDs for the slow-2 and slow-4 bands. In the TBI
population on the other hand, all trials saw APDs at the HUT position for all five slow
bands. A summary of these observations is shown in Figure 19 below.

FIGURE 19: The prevalence of average power increases (APIs) and decreases (APDs) from the subjects at
the HUT position in comparison to their resting position power. (Left) Compares APIs and APDs in the
non-TBI trials and (right) compares them in the TBI trials.

To take the magnitude of the percent changes into consideration, we averaged the percent
changes of the trials within each population and slow band to determine the overall
population effects of the HUT position. These results are summarized in Figure 19 below.
In the slow-1 band of the non-TBI trials, we observed an overall 33.5% increase in power
with HUT, despite there being more prevalence of APDs for this band. Two subjects with
a 363% and 122% increase respectively largely influenced the overall average increase and
show the strength of assessing change on an individual basis. In the slow-1 band of the TBI
trials, we observed an overall 5.3% decrease in power with HUT consistent with the
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prevalence of decreases within those trials. Looking at Figure 20, it is evident that
individual trials within the non-TBI group exhibited similar LFO effects to the TBI trials
suggesting that the effects of HOB manipulation are more representative of individual brain
variability rather than brain injury effects. In the slow-2 band of the non-TBI trials, we
observed an overall 0.9% decrease in power with HUT consistent with an equal presence
of APIs and APDs for these trials. In the slow-2 band of the TBI trials, we observed an
overall 13.2% decrease in power with HUT consistent with the prevalence of APDs. In the
slow-3 band of the non-TBI trials, we saw an overall 5.1% increase in power with HUT
consistent with the higher prevalence of APIs, however this increase is smaller and not
representative of some increases as large as 59%. In the non-TBI trials we saw an overall
20.2% decrease also consistent with its prevalence of APDs in that population. In the slow4 band of the non-TBI trials, we saw an overall 4.0% decrease in power with HUT
representative of the equal prevalence of APIs and APDs in that band. In the slow-4 band
of the TBI trials, we observed an 18.9% decrease representative of the APDs in that band.
In the slow-5 band of the non-TBI trials, we saw an overall 10.6% increase in power with
HUT consistent with the prevalence of APIs. However, the percent changes varied from as
high as 107.9% and as low as 7.1% suggesting once again the individuality of cerebral
response to HOB manipulation. In the TBI trials, we saw an overall 38.8% decrease largely
influenced by a 64.6% decrease observed in the second trial and consistent with the
prevalence of APDs within that population.
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FIGURE 20: The average of percent changes comparing subjects at the HUT position to their resting
position within each population and slow band.

The similarity of changes between the TBI trials, obtained from the same subject, suggest
fNIRS is adequately detecting meaningful LFOs. Since there is small intrasubject
variability, it suggests the LFO percent changes are representative of that subject’s
oscillatory mechanisms.
An average value of PSD magnitude was then obtained at each slow band to allow for
comparison between the non-TBI and the TBI trials within each HOB position. Exact PSD
values in uM2/Hz are recorded in Table 5 in the Appendix and the results are summarized
in Figure 21 below.
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FIGURE 21: Comparison of average PSD of the non-TBI trials and TBI trials during (left) HUT and
(right) the Rest position. These values can be found in Table 5 in the Appendix.

Regarding the HUT position, the non-TBI trials showed a higher power than the TBI trials
in all the slow bands except for the slow-4 band. Similarly in the resting position, the nonTBI trials showed a higher power in all the slow bands except for the slow-4 and slow-5
bands. By having higher spontaneous activity of slow-1, slow-2, and slow-3 LFOs in nonTBI trials at both HOB positions, these results convey that within these three slow bands,
the uninjured brain is more active than the injured brain in the mechanisms each of those
bands represent. This suggests that with injury comes a decrease in activity for those three
bands. Conversely, by having higher spontaneous activity of slow-4 LFOs in TBI trials at
both HOB positions, these results convey that injury increases activity of the mechanism
that the slow-4 band represents. This differentiation at the slow-4 band relates to a previous
study that found differences from healthy controls in the slow-4 and slow-5 frequency
band, however that study measured the occipital region of the brain139.

3.3.8 Slow Band Max Power Analysis
For the second analysis, the maximum PSD magnitude of each slow band was individually
isolated from each trial in MATLAB 2018b and recorded in Table 6 in the Appendix.
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Percent change was once again used to assess the effects of HOB manipulation and these
changes are recorded in Table 7 in the Appendix.
In the non-TBI population, APIs were more prevalent at the HUT position for the slow-1,
slow-3, and slow-4 bands, and APDs were more prevalent for the slow-2 and slow-5 bands.
In the TBI population, APIs were more prevalent at the slow-2 and slow-3 bands, and APDs
were more prevalent at the slow-1, slow-4, and slow-5 bands . A summary of these
observations is shown in Figure 22 below.

FIGURE 22: The prevalence of max power increases (APIs) and decreases (APDs) from the subject at the
HUT position in comparison to their resting position power. (Left) Compares APIs and APDs in the nonTBI trials and (right) compares them in the TBI trials.

As before, we considered the magnitude of the percent changes by averaging the magnitude
of the percent changes within each band of the two populations. These results are
summarized in Figure 23 below. It is important to note, however, that while the spectrums
were similar amongst trials, the maximum PSD did not occur at the same frequency within
each band. Therefore, an average percent change of maximum power represents more the
responsiveness of LFOs within each band rather than the changes of a specific frequency.
In the slow-1 band of the non-TBI trials, we observed an overall 16.2% increase in
maximum power values with HUT consistent with more prevalence of APIs. In the slow1 band of the TBI trials, we observed an overall 23.3% decrease in maximum power
consistent with prevalence of APDs within those trials. In the slow-2 band of the non-TBI
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trials, we observed an overall 8.5% decrease in maximum powers with HUT consistent
with higher prevalence of APDs. However, one trial decreased by as much as 53.4% and
as low as 2% showing large intersubject variability and the need to look at individual
responses more on a case-by-case basis. In the slow-2 band of the TBI trials, we observed
an overall 9.6% increase in maximum power consistent with prevalence of APIs within
those trials. In the slow-3 band of the non-TBI trials, we observed an overall 13.2% increase
in power values consistent with the prevalence of APIs. In the non-TBI trials, we observed
an overall 0.7% increase consistent with the prevalence of small APIs within that
population. In the slow-4 band of the non-TBI trials, we saw an overall 6.3% increase in
maximum power consistent with the prevalence of APIs with HUT, however this small
increase is not representative of trials that saw increases as large as 62.3%. In the slow-4
band of the TBI trials, we saw an overall 12.9% decrease consistent with the prevalence of
APDs. In the slow-5 band of the non-TBI trials, we saw a small 2.4% overall increase in
maximum power inconsistent with the larger prevalence of APDs in trials. An average
increase in maximum power was most likely influenced by trials with increases as large as
68.4% and trials with decreases as small as 4.7%. Therefore, despite more non-TBI subjects
experiencing a decrease in maximum power with HUT, the overall effects for that
population suggests HUT minutely increases the power of maximum frequencies in the
slow-5 band. In the slow-5 band of the TBI trials, we saw an overall 4.6% decrease in
maximum power consistent with the higher prevalence of small APDs.
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FIGURE 23: The average of max percent changes comparing subjects at the HUT position to their resting
position within each population and slow band.

As with the average value analysis, the average of maximum PSD magnitudes was also
obtained at each slow band to allow for comparison of responsiveness between the nonTBI and the TBI trials within each HOB position. Exact PSD values in uM2/Hz are recorded
in Table 8 in the Appendix and the results are summarized in Figure 24 below.

FIGURE 24: Comparison of max PSD of the non-TBI trials and TBI trials during (left) HUT and (right)
the Rest position. These values can be found in Table 8 in the Appendix.

Regarding the HUT position, the non-TBI trials showed a higher maximum power than the
TBI trials in all the slow bands except for the slow-2 band. Similarly in the resting position,
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the non-TBI trials showed a higher maximum power in all the slow bands except for the
slow-1 and slow-2 bands. By having higher maximum spontaneous activities within the
slow-3, slow-4, and slow-5 bands in non-TBI trials at both HOB positions, these results
convey that within these three slow bands, the uninjured brain has a stronger LFO response
than the injured brain. This suggests that with injury comes a decrease in responsiveness
for those three bands. Conversely, by having higher maximum powers within the slow-2
band in TBI trials at both HOB positions, these results convey that injury increases
responsiveness of LFOs in the slow-4 band.
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4. Limitations and Alternative Strategies
A limiting factor of this project was subject recruitment as it was on an
opportunity basis for both populations. We were only able to recruit one TBI subject and
performed measurements after the injury had occurred. Due to the limiting sample size of
this group, we obtained three measurements from this same subject to represent the TBI
population. The non-TBI control population was also obtained on an opportunity-basis,
but due to higher sample-size, each control subject received one measurement. Therefore,
this project serves to be descriptive and preliminary as a pilot study, rather than
conclusive. It can be used as reference for future studies where increased subject
recruitment would provide statistical power. To illustrate the limitation of this project to
produce statistically conclusive results, a power analysis was conducted.
Power is defined as the probability of detecting a statistically significant
difference given that the difference actually exists. The gold standard is 80% power,
which was used in these power analyses. An overall level of significance of α=0.05 was
used throughout. RStudio version 1.3.1073 was used for the analyses. Descriptive
statistics by group are given below in Table 1.
TABLE 1: Descriptive statistics of hemodynamic concentration changes
Variable

Group

N

Mean

Std Dev

Minimum

Maximum

Change HbO

Non-TBI

TBI

12
3
12
3

0.49
0.34
-0.05
0.53

0.58
1.03
-

-0.95
-0.42
-1.53
-0.87

1.06
0.79
1.75
2.43

Non-TBI

12

0.44

0.59

-0.78

1.24

3

0.87

-

-0.36

1.31

TBI
Change Hb

Change THC

Non-TBI

TBI
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Since there was only one TBI patient, we cannot estimate the standard deviation for that
group. Therefore, we must assume that the two groups have the same standard deviation,
which may or may not be the case. This means the estimate for the non-TBI group was
used as the estimate for the pooled standard deviation for both groups in the power
analyses. However, there may be more variance in the TBI group, which means that the
recommended sample sizes need to be larger than what are included in this power
analysis. All power analyses are for independent samples t-tests.
The results of the power analysis are given in Table 2 below.
TABLE 2: Power analysis results
Variable
Change HbO
Change Hb
Change THC

Group

Mean

Non-TBI
TBI
Non-TBI
TBI
Non-TBI
TBI

0.49
0.34
-0.05
0.53
0.44
0.87

Pooled
S.D.
0.58

n per
Group
235

1.03

50

0.59

1116

The number of subjects per group needed to achieve 80% power from the statistics of
this project is given in the far-right column. For example, the table indicates that 235
subjects per group (470 total subjects) are required to achieve 80% power for the change
in HbO. Since we are taking the measurements from the same subjects, we would have to
go with the largest sample size to achieve at least 80% power for all response
variables. This means that we would need 1116 subjects per group (2232 total subjects
from the Change THC variable), which was not feasible.
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5. Conclusions & Future Work
Overall this project aimed to characterize the cerebral response of a non-TBI and
a TBI population using frequency domain analysis of the fNIRS signal. Twelve non-TBI
subjects underwent one optical measurement each and one TBI subject underwent three
optical measurements of their DPFC following a HOB manipulation protocol.
In the time-domain, both groups showed an overall increase in HbO with HOB lowering,
consistent with previous studies. Hb slightly decreased in the non-TBI group, but largely
increased in the TBI group with HOB lowering. At the lower resting position, gravity no
longer assists the brain with venous return and these concentration results show the effect
of pooling. The TBI subject was significantly more affected by this than the non-TBI
subjects and shows the potential effect of trauma on the brain’s ability to autoregulate.
In the FD, we analyzed LFOs from the HbO time-domain signal. HbO was the
hemodynamic parameter of choice for frequency analysis as it is representative of brain
activity. In the HUT position, spontaneous oscillations around 0.1 Hz were present with
similar magnitude in both study groups. This is consistent with previous studies identifying
0.1 Hz activity in the MAP and CBFV signals. This 0.1 Hz activity was also present in the
resting position whereas in that previous study the resting position did not show 0.1 HZ
LFO activity. Since their protocol began in the resting position and elevated their subjects,
while this project began in HUT and then lowered subjects, 0.1 Hz might be more present
at elevated positions and remain as a lingering mechanism in our project’s resting
measurements. LFOs near 0.027 Hz were present in the TBI group at the HUT position,
but not in the non-TBI group or in either group at the resting position. Activity in a study
on ASD children exhibited similar results suggesting this oscillation represents a
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malfunctioning neurogenic mechanism observable at the HUT position. The ~0.027 Hz
frequency, therefore becomes an identifiable feature of diseased brain states and should be
followed up in subsequent studies, and the HUT position emerges as an ideal elevation
under which to perform these measurements. A higher overall power in the HUT responses
of the non-TBI group and more focused peaks also show the strength of using an elevated
position when assessing LFO responses.
Previous studies have identified specific frequencies of interest when studying
LFOs including 0.0133, 0.04, 0.067, 0.0933, and 0.1 Hz. This project also identified
prevalence in the same LFOs of 0.0133, 0.08, 0.0933, and 0.1Hz. Additionally, 0.053 and
0.067 Hz were prevalent LFO peaks amongst subjects. These peaks also fall into ranges of
LFOs called slow-bands that have been previously defined in a study139. We defined APIs
as percent increases in power spectral density with the HUT position and APDs as percent
decreases. Regarding average PSD, for non-TBI, APIs were more prevalent in the slow-3
and 5 bands, APDs in the slow-1 band, and equivalent occurrences of APIs and APDs in
the slow-2 and 4 bands. In the TBI trials, all slow bands exhibited APDs. The overall
average PSD change in each band (Figure 19) also showed percent decreases in all slowbands in the TBI trials. This suggests, at least for the TBI subject in this project, that trauma
causes decreased activity at the HUT position and shows the strength of using the HUT
position when analyzing LFOs and characterizing TBI. This differentiation between nonTBI and TBI and consistency between APIs, APDs, and averaged PSDs was not as
pronounced in the maximum analysis and therefore this project favors an analysis of
average PSD within each band when studying cerebral response. Comparison of slowbands between study groups was also possible with this analysis of average PSD within
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each band. Regarding the HUT position, the non-TBI trials showed a higher power than
the TBI trials in all the slow bands except for the slow-4 band. Similarly in the resting
position, the non-TBI trials showed a higher power in all the slow bands except for the
slow-4 and slow-5 bands. By having higher spontaneous activity of slow-1, slow-2, and
slow-3 LFOs in non-TBI trials at both HOB positions, these results convey that within
these three slow bands, the uninjured brain is more active than the injured brain in the
mechanisms each of those bands represent. This suggests that with injury comes a decrease
in activity for those three bands. Conversely, by having higher spontaneous activity of
slow-4 LFOs in TBI trials at both HOB positions, and slow-5 in the resting position, these
results convey that injury increases activity of the mechanism that the slow-4 band
represents and slow-5 band at lowered positions. This is interesting as a previous study on
preterm and term infants showed an inverse correlation between LFO activity and brain
function16. Since the slow-4 and slow-5 bands have been shown to represent neurogenic
and endothelial mechanisms respectively, this project consistently shows increased LFO
response with inhibited brain function.
While this study used a time-series filter to individually assess LFOs at the HUT
position and the Rest position, future studies could also look at the transition period to see
if meaningful frequency or time domain information could characterize trauma in the brain
as the elevation change is happening.
Finally, this project also showed the need of cerebral assessment to be taken on a
case-by-case basis. Analyzing individual spectrums, subjects showed unique responses
regardless of whether they were in the non-TBI or TBI group. The sole TBI subject who
had three trials exhibited a similar response in all three measurements showing the
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repeatability and precision of their cerebral assessment using fNIRS derived LFOs. This
higher intersubject variability and lower intrasubject variability show the strength of
individually assessing and characterizing cerebral response. Future studies should focus
on recruiting more subjects and performing repeated measures to further validate this.
However, this project illustrates the strength of a practical tool in fNIRS and assessment
of LFOs to conveniently provide personalized assessment of unique cerebral response.
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Appendix

FIGURE 25: Example FD series of a non-TBI trial’s HbO LFO spectrum used in the frequency prevalence
analysis. (Left) Time progression of the frequency spectrums including two plots with transition periods
and (Right) the time-series filtered frequency spectrums that were used to isolate frequency peaks. A
frequency was considered a peak if its PSD magnitude was greater than the value of its neighboring
observations.

FIGURE 26: Example of an individual HbO spectrum at the two HOB positions.

TABLE 3: The average power spectrum densities in units of uM2/Hz for each trial at each HOB elevation.

Trial
Healthy 1

Slow-1 Avg.
PSD HUT
0.0058533

Slow-2 Avg.
PSD HUT

Slow-3 Avg.
PSD HUT

0.012077

0.026786
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Slow-4 Avg.
PSD HUT
0.01099

Slow-5 Avg.
PSD HUT
0.024086

Healthy 2
Healthy 3
Healthy 4
Healthy 5
Healthy 6
Healthy 7
Healthy 8
Healthy 9
Healthy 10
Healthy 11
Healthy 12
TBI 1
TBI 2
TBI 3
Trial
Healthy 1
Healthy 2
Healthy 3
Healthy 4
Healthy 5
Healthy 6
Healthy 7
Healthy 8
Healthy 9
Healthy 10
Healthy 11
Healthy 12
TBI 1
TBI 2
TBI 3

0.0024063
0.0020352
0.00396
0.0012505
0.0024371
0.0022502
0.01034
0.0049748
0.011716
0.0084212
0.00528
0.0088066
0.0033963
0.0014711
Slow-1 Avg.
PSD Rest
0.0052053
0.0025979
0.0024101
0.0045794
0.0013517
0.0026072
0.0023126
0.0046608
0.0054107
0.011633
0.010157
0.0055259
0.0092678
0.0036188
0.0015433

0.0058102
0.0055107
0.0060064
0.0021719
0.0030778
0.004942
0.022011
0.0073331
0.024548
0.013986
0.0067909
0.014211
0.0056459
0.0022196
Slow-2 Avg.
PSD Rest

0.021885
0.01815
0.014461
0.007388
0.006882
0.013651
0.070983
0.02032
0.05477
0.041189
0.014356
0.035764
0.013926
0.0087932
Slow-3 Avg.
PSD Rest

0.0094206
0.006307
0.0062453
0.0080672
0.0023778
0.0029779
0.0044226
0.015042
0.0071578
0.02326
0.019949
0.0090585
0.016086
0.0060917
0.0027913

0.021271
0.021258
0.018104
0.019969
0.0070394
0.0060811
0.011918
0.044635
0.016734
0.049115
0.05738
0.022916
0.040203
0.01946
0.011133

0.0089512
0.0052627
0.011459
0.0057976
0.0050882
0.0035232
0.018578
0.011379
0.01374
0.011197
0.0095878
0.024851
0.008314
0.0069216
Slow-4 Avg.
PSD Rest
0.010756
0.0071588
0.0050307
0.010398
0.005089
0.005621
0.010126
0.018773
0.0096799
0.014043
0.017124
0.010478
0.02664
0.013841
0.0077034

0.022026
0.033223
0.04184
0.025077
0.013444
0.015635
0.058443
0.03717
0.045818
0.054012
0.025711
0.04967
0.018306
0.019034
Slow-5 Avg.
PSD Rest
0.011587
0.030599
0.031032
0.035294
0.016392
0.011715
0.027803
0.061069
0.02805
0.039184
0.12825
0.023282
0.072887
0.051721
0.02378

TABLE 4: The percent change of average PSD defined as 100 x (PSDHUT – PSDREST )/ PSDREST for each
trial. This metric was used to assess the effects of HOB manipulation in the non-TBI and TBI trials.

Trial
Healthy 1
Healthy 2
Healthy 3

% Change
Slow-1

% Change
Slow-2

% Change
Slow-3

% Change
Slow-4

% Change
Slow-5

362.7206885
-7.375187652
-15.55537115

28.19777933
-7.876962106
-11.76244536

25.92731888
2.949477844
0.254087494

2.175529937
25.03771582
4.611684259

107.8708898
-28.01725547
7.060453725
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Healthy 4
Healthy 5
Healthy 6
Healthy 7
Healthy 8
Healthy 9
Healthy 10
Healthy 11
Healthy 12
TBI 1
TBI 2
TBI 3

-13.5257894
-7.486868388
-6.524240565
-2.698261697
121.8503261
-8.056258894
0.713487492
-17.08969184
-4.449953854
-4.976369796
-6.148446999
-4.678286788

-25.54541848
-8.659264867
3.354713053
11.74422286
46.33027523
2.449076532
5.537403267
-29.89122262
-25.03284208
-11.65609847
-7.31815421
-20.48149608

-27.58275327
4.952126602
13.17031458
14.54103037
59.02990926
21.42942512
11.51379416
-28.21714883
-37.35381393
-11.04146457
-28.43782117
-21.01679691

10.20388536
13.92415013
-9.478740438
-65.20639937
-1.03872583
17.55286728
-2.15765862
-34.61224013
-8.495896163
-6.715465465
-39.93208583
-10.14876548

18.54706182
52.98316252
14.75885617
-43.76506132
-4.300054037
32.51336898
16.93037975
-57.88538012
10.4329525
-31.85341693
-64.60625278
-19.95794786

TABLE 5: Average power spectrum densities (PSDs) in units of uM2/Hz of the non-TBI trials and TBI
trials during HUT and the Rest position.

Study Group
& Elevation

Average
PSD Slow-1

Average
PSD Slow-2

Average
PSD Slow-3

Average
PSD Slow-4

Average
PSD Slow-5

non-TBI HUT
TBI HUT
non-TBI Rest
TBI Rest

0.00507705

0.009522083

0.02590175

0.009629475

0.033040417

0.004558

0.007358833

0.0194944

0.0133622

0.029003333

0.004870967
0.004809967

0.009523808
0.008323

0.024701708
0.023598667

0.01035645
0.016061467

0.037021417
0.049462667

TABLE 6: The max power spectrum densities in units of uM2/Hz for each trial at each HOB elevation.

Trial

Slow-1 Max
PSD HUT

Slow-2 Max
PSD HUT

Slow-3 Max
PSD HUT

Slow-4 Max
PSD HUT

Slow-5 Max
PSD HUT

Healthy 1
Healthy 2
Healthy 3
Healthy 4
Healthy 5
Healthy 6
Healthy 7
Healthy 8
Healthy 9
Healthy 10
Healthy 11
Healthy 12
TBI 1
TBI 2

0.041415441
0.046493474
0.107250112
0.09688213
0.048869434
0.021572006
0.043512274
0.152269569
0.063140951
0.112594479
0.141450972
0.050570005
0.097807968
0.037529432

0.030897162
0.021613898
0.010878272
0.017249898
0.01210692
0.01155927
0.008192022
0.032282062
0.020043941
0.026879262
0.026319692
0.020989033
0.058707282
0.017481989

0.34953747
0.158180259
0.147688067
0.055350267
0.05492372
0.036655193
0.0790534
0.475013974
0.088018456
0.51825385
0.303309593
0.077549801
0.193982
0.08520546

0.105975573
0.031468553
0.026289532
0.015106703
0.012695942
0.008961974
0.026031644
0.12666653
0.022254097
0.13530751
0.087426789
0.020352816
0.066783012
0.021027168

0.015210128
0.00459418
0.004097818
0.007177779
0.002492808
0.004390495
0.005071375
0.026272386
0.00842813
0.023828847
0.020715698
0.009134317
0.015563387
0.00634762
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TBI 3
Trial
Healthy 1
Healthy 2
Healthy 3
Healthy 4
Healthy 5
Healthy 6
Healthy 7
Healthy 8
Healthy 9
Healthy 10
Healthy 11
Healthy 12
TBI 1
TBI 2
TBI
3

0.05549432

0.024602707

0.064468184

0.008191126

0.003002197

Slow-1 Max
PSD Rest

Slow-2 Max
PSD Rest

Slow-3 Max
PSD Rest

Slow-4 Max
PSD Rest

Slow-5 Max
PSD Rest

0.019371803
0.071576576
0.097851659
0.077094575
0.036203851
0.018880242
0.052467942
0.115159437
0.060955082
0.086127916
0.256871271
0.039948889
0.123055108
0.096354686

0.024928405
0.02065786
0.008208015
0.018151697
0.014213541
0.011741398
0.015593188
0.030558672
0.01773255
0.043432042
0.056429396
0.026625947
0.052320538
0.023335007

0.221804376
0.13104969
0.131272694
0.089058089
0.042873863
0.03402787
0.070118501
0.315033963
0.080059354
0.325307132
0.319436409
0.184766811
0.243364557
0.073425327

0.065167661
0.029394198
0.038761062
0.026637084
0.012714772
0.008742026
0.017461129
0.083073291
0.020066955
0.118047834
0.074081312
0.060543868
0.073483686
0.020226078

0.012919589
0.005146889
0.005226595
0.009005438
0.002313103
0.004612373
0.004142972
0.015596904
0.011149166
0.025002175
0.018095973
0.010736774
0.017277063
0.007140776

0.049700692

0.01736448

0.06066677

0.012325084

0.002803348

TABLE 7: The percent change of max PSD defined as 100 x (PSDHUT – PSDREST )/ PSDREST for each trial.
This metric was used to assess the effects of HOB manipulation in the non-TBI and TBI trials.

Trial

% Change
Slow-1

% Change
Slow-2

% Change
Slow-3

% Change
Slow-4

% Change
Slow-5

Healthy 1
Healthy 2
Healthy 3
Healthy 4
Healthy 5
Healthy 6
Healthy 7
Healthy 8
Healthy 9
Healthy 10
Healthy 11
Healthy 12
TBI 1
TBI 2
TBI 3

113.7923863
-35.04373008
9.604796381
25.66659844
34.98407656
14.25704458
-17.06883715
32.22500384
3.586033351
30.72936669
-44.93312881
26.58676212
-20.51693811
-61.05074597
11.65703577

23.94360005
4.62796245
32.53229904
-4.968127044
-14.82122986
-1.551162443
-47.4640995
5.639611474
13.03474053
-38.11190726
-53.35819031
-21.17075586
12.20695267
-25.08256631
41.68409335

57.58817583
20.70250557
12.50478814
-37.84925396
28.10536743
7.721092651
12.7425704
50.78182974
9.941500755
59.3121698
-5.048521548
-58.02828417
-20.29159756
16.04369124
6.266057562

62.61988155
7.057020718
-32.17540796
-43.28694829
-0.148093478
2.515988705
49.08339527
52.47563767
10.89922269
14.62091687
18.01463343
-66.38335736
-9.118587396
3.960680565
-33.54101521

17.72918915
-10.73868782
-21.59678548
-20.29505336
7.769006586
-4.81048818
22.40909552
68.44616124
-24.40573803
-4.69290314
14.47683927
-14.92494257
-9.918787143
-11.1074271
7.09326447
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TABLE 8: Max power spectrum densities (PSDs) in units of uM2/Hz of the non-TBI trials and TBI trials
during HUT and the Rest position.

Study Group
& Elevation

Max PSD
Slow-1

Max PSD
Slow-2

Max PSD
Slow-3

Max PSD
Slow-4

Max PSD
Slow-5

non-TBI HUT
TBI HUT
non-TBI Rest
TBI Rest

0.077168404

0.019917619

0.195294504

0.051544805

0.010951164

0.063610573

0.033597326

0.114551881

0.032000435

0.008304401

0.077709104
0.089703496

0.024022726
0.031006675

0.162067396
0.125818884

0.046224266
0.035344949

0.010328996
0.009073729
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